LightPath Technologies, Inc. — Form 10-Q Summary
Business context and reporting period. This filing covers the three months ended September 30, 2023, LightPath’s first quarter of fiscal 2024, compared with the same quarter of fiscal 2023. LightPath designs and manufactures optical components, assemblies and modules, and provides engineering services. It is pursuing a strategic shift toward higher-value engineered solutions. Financial statements are unaudited.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Revenue | $8.08 million | $7.37 million |
| Gross profit / gross margin | $2.33 million / 29% | $2.23 million / 30% |
| Operating loss | $1.25 million | $1.24 million |
| Net loss | $1.34 million; $0.04 per share | $1.38 million; $0.05 per share |
| EBITDA, non-GAAP | Loss of $432,000 | Loss of $392,000 |
| Cash from operating activities | Provided $1.14 million | Used $415,000 |
At September 30, 2023, cash and cash equivalents were $4.32 million, with another $2.54 million classified as restricted cash. Working capital was approximately $11.4 million. Total loans payable were approximately $2.51 million, including about $2.0 million outstanding under the BankUnited term loan. The term loan bears interest at 8.5%, matures December 31, 2024, and requires refinancing or repayment at maturity. Lease liabilities totaled $10.24 million, primarily long-term facility operating leases.
Changes versus the prior comparable period
- Revenue rose 10%. Infrared components increased 20% to $3.83 million, primarily on shipments under an international military contract. Assemblies and modules rose 45% to $1.26 million, while engineering services increased to $292,000. Visible components fell 18% to $2.69 million, reflecting weaker China telecommunications and U.S. and European catalog/distribution sales.
- Gross profit increased 4%, but gross margin declined from 30% to 29%. Management attributed the margin decline to a higher mix of infrared components and lower sales of typically higher-margin visible components.
- Net loss narrowed by approximately $38,000, mainly due to a lower income tax provision. Operating loss was slightly higher, and EBITDA loss widened by approximately $40,000.
- Operating cash flow improved from an outflow to an inflow, largely because of lower accounts receivable. Investing outflows increased with facility expansion, capital spending and the Visimid acquisition.
- Weighted-average shares increased to 37.43 million from 27.07 million, primarily reflecting the January 2023 public offering of 9.09 million shares.
Outlook, management commentary and risks
- In July 2023, LightPath acquired Visimid Technologies, an engineering and design firm focused on thermal imaging, night vision and IoT applications. The estimated purchase price, including an estimated contingent earnout and net of cash acquired, was approximately $2.9 million. Purchase accounting remains provisional pending valuations.
- Management reported total backlog of approximately $21.3 million at quarter-end, down 7% year over year and 2% from fiscal year-end. The decline reflected shipments against previously booked annual and multiyear orders. Management anticipates renewals of existing contracts, but timing can vary. A significant international military contract renewal was approximately 40% higher in dollar value than its prior order.
- Management expects no significant near-term growth in visible components. It cited slow bookings in China, economic weakness there, and uncertainty about the timing of commercialization for some newer molding capabilities. The company sees demand potential for infrared products and alternative materials, including its BD6 material.
- The Orlando facility expansion received a $2.4 million landlord tenant-improvement allowance; LightPath estimates its remaining share of project costs at approximately $3.8 million. It spent $890,000 on the project in the quarter and expected to spend a further approximately $550,000 in Q2 FY2024, subject to final invoices.
- LightPath has begun discussions with prospective lenders to refinance the BankUnited term loan before its December 2024 maturity. Management cautions that refinancing on reasonable terms is not assured; failure to refinance could require additional equity or other financing, or reductions in operating expenses and capital expenditures. The company was in compliance with required loan covenants at quarter-end.
- Risks highlighted include weaker Chinese demand and operating conditions, supply and cost pressures, geopolitical disruption including the Russia-Ukraine conflict and Hamas-Israel war, and continuing impacts from COVID-related conditions and travel constraints. Management said it cannot precisely estimate certain future effects.
- Management stated disclosure controls were effective and reported no significant changes in internal control over financial reporting. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Whether backlog converts to revenue and contract renewals occur on expected terms, particularly the military program and the medical customer end-of-life order extending into fiscal 2025.
- Progress and final purchase accounting for Visimid, including the contingent earnout, remaining stock consideration and expected contribution to growth and profitability.
- Cash availability for operations and expansion, given that $2.54 million was restricted and more than 25% of cash and cash equivalents was held by foreign subsidiaries.
- Refinancing plans, the December 2024 loan maturity, the 8.5% interest rate and scheduled exit fees.
- Whether revenue growth can improve margins and reduce operating losses, particularly amid weaker visible-component sales and continuing investment needs.